CompletedPhase 2NCT00003778
Dolastatin 10 in Treating Patients With Recurrent or Metastatic Soft Tissue Sarcoma
Studying Sarcoma of the corpus uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Margaret von Mehren, MDFox Chase Cancer Center
- Intervention
- dolastatin 10(drug)
- Enrollment
- 37 target
- Eligibility
- 18 years · All sexes
- Timeline
- 1999
Study locations (4)
- University of Colorado Cancer Center, Denver, Colorado, United States
- Mayo Clinic Cancer Center, Rochester, Minnesota, United States
- Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
- Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00003778 on ClinicalTrials.gov